An Emergent BioSolutions Inc. investor sued its current and former leaders in Delaware, claiming they sold millions worth of stock while hiding manufacturing problems that later spoiled millions of doses of the Covid-19 vaccines the company was making for
The derivative lawsuit, made public Tuesday, accuses Emergent CEO Robert G. Kramer and five other board members of insider trading. It also hits other top company officers and directors with fiduciary breach claims that don’t involve insider trading allegations.
They sold a combined $21 million worth of stock—including $10 million in sales by Kramer alone—based ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.